NCT02641457View on ClinicalTrials.gov

Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis

PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

October 31, 2015

Conditions
GlaucomaRubeosis Iridis
Interventions
DRUG

Aflibercept

12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.

DRUG

Ranibizumab

12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.

Trial Locations (1)

74110-120

Instituto de Olhos de Goiania, Goiânia

All Listed Sponsors
lead

Instituto de Olhos de Goiania

OTHER

NCT02641457 - Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis | Biotech Hunter | Biotech Hunter